Heart failure biomarkers: Focus on interleukin-1 receptor-like 1-based blood tests

Drugs of Today

Volumn 48, Issue 7, 2012, Pages 479-491

  Broch, K ^a,b   Ueland, T ^a   Yndestad, A ^a   Aukrust, P ^a,b   Gullestad, L ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Biomarkers; Heart failure; IL1RL1; Interleukin 1 receptor like 1; Interleukin 33

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR LIKE 1; INTERLEUKIN 1 RECEPTOR LIKE 1 ISOFORM B; INTERLEUKIN 33; ISOPROTEIN; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; AGE; ARTICLE; BLOOD EXAMINATION; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMIC STRESS; HUMAN; INFLAMMATION; NONHUMAN; NORMAL VALUE; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; HEART FAILURE; HEMODYNAMICS; HUMANS; INFLAMMATION; MYOCYTES, CARDIAC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 84864798811     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.7.1811719     Document Type: Article

References (113)

1. Roger, V.L., Go, A.S., Lloyd-Jones, D.M. et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012, 125(1): e2-e220.
2. Dickstein, K., Cohen-Solal, A., Filippatos, G. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10(10):933-89.
3. Hunt, S.A., Abraham, W.T., Chin, M.H. et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53(15): e1-e90.
4. van Kimmenade, R.R., Januzzi, J.L., Jr. Emerging biomarkers in heart failure. Clin Chem 2012, 58(1): 127-38.
5. Hunt, S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46(6): e1-82.
6. Pfeffer, J.M., Pfeffer, M.A., Braunwald, E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985, 57(1): 84-95. (Pubitemid 15238844)
7. Opie, L.H., Commerford, P.J., Gersh, B.J., Pfeffer, M.A. Controversies in ventricular remodelling. Lancet 2006, 367(9507): 356-67. (Pubitemid 43151469)
8. Modesti, P.A., Vanni, S., Bertolozzi, I. et al. Early sequence of cardiac adaptations and growth factor formation in pressure-and volume-overload hypertrophy. Am J Physiol Heart Circ Physiol 2000, 279(3): H976-85.
9. Yndestad, A., Damas, J.K., Oie, E., Ueland, T., Gullestad, L., Aukrust, P. Systemic inflammation in heart failure - the whys and wherefores. Heart Fail Rev 2006, 11(1): 83-92. (Pubitemid 43986210)
10. Valen, G. Innate immunity and remodelling. Heart Fail Rev 2011, 16(1): 71-8.
11. Gajarsa, J.J., Kloner, R.A. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev 2011, 16(1): 13-21.
12. Pfeffer, M.A., Braunwald, E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81(4): 1161-72. (Pubitemid 20119612)
13. Schaper, J., Froede, R., Hein, S. et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 1991, 83(2): 504-14.
14. D'Armiento, J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med 2002, 12(3): 97-101. (Pubitemid 34462178)
15. Shafazand, M., Schaufelberger, M., Lappas, G., Swedberg, K., Rosengren, A. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. Eur Heart J 2009, 30(6): 671-8.
16. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327(10): 685-91.
17. Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M., Shusterman, N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334(21): 1349-55. (Pubitemid 26152713)
18. Pitt, B., Zannad, F., Remme, W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341(10): 709-17. (Pubitemid 29407370)
19. Huang, Y., Wu, W., Cao, Y., Qu, N. All cause mortality of cardiac resynchronization therapy with implantable cardioverter defibrillator: a meta-analysis of randomized controlled trials. Int J Cardiol 2010, 145(3): 413-7.
20. McAlister, F.A., Ezekowitz, J., Hooton, N. et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007, 297(22): 2502-14. (Pubitemid 46953404)
21. Felker, G.M., Thompson, R.E., Hare, J.M. et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342(15): 1077-84. (Pubitemid 30207690)
22. Levy, W.C., Mozaffarian, D., Linker, D.T. et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006, 113(11): 1424-33. (Pubitemid 43739439)
23. Aaronson, K.D., Schwartz, J.S., Chen, T.M., Wong, K.L., Goin, J.E., Mancini, D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997, 95(12): 2660-7. (Pubitemid 27255495)
24. Ketchum, E.S., Levy, W.C. Multivariate risk scores and patient outcomes in advanced heart failure. Congest Heart Fail 2011, 17(5): 205-12.
25. Braunwald, E. Biomarkers in heart failure. N Engl J Med 2008, 358(20): 2148-59.
26. Morrow, D.A., de Lemos, J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115(8): 949-52. (Pubitemid 46328287)
27. Hosoda, K., Nakao, K., Mukoyama, M. et al. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension 1991, 17(6, Pt. 2): 1152-5.
28. Magga, J., Marttila, M., Mantymaa, P., Vuolteenaho, O., Ruskoaho, H. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats. Endocrinology 1994, 134(6): 2505-15. (Pubitemid 24170864)
29. Martinez-Rumayor, A., Richards, A.M., Burnett, J.C., Januzzi, J.L., Jr. Biology of the natriuretic peptides. Am J Cardiol 2008, 101(3A): 3-8.
30. Richards, A.M., Troughton, R.W. Use of natriuretic peptides to guide and monitor heart failure therapy. Clin Chem 2012, 58(1): 62-71.
31. Adams, K.F., Jr., Felker, G.M., Fraij, G., Patterson, J.H., O'Connor, C.M. Biomarker guided therapy for heart failure: focus on natriuretic peptides. Heart Fail Rev 2010, 15(4): 351-70.
32. O'Connor, C.M., Starling, R.C., Hernandez, A.F. et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011, 365(1): 32-43.
33. Christ, M., Laule-Kilian, K., Hochholzer, W., Klima, T., Breidthardt, T., Perruchoud, A.P., Mueller, C. Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol 2006, 48(9): 1808-12. (Pubitemid 44648609)
34. Wu, A.H., Omland, T., Wold, K.C. et al. Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. Am J Hematol 2005, 80(3): 174-80. (Pubitemid 41579538)
35. Hogenhuis, J., Voors, A.A., Jaarsma, T., Hoes, A.W., Hillege, H.L., Kragten, J.A., van Veldhuisen, D.J. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail 2007, 9(8): 787-94. (Pubitemid 47212827)
36. Daniels, L.B., Clopton, P., Bhalla, V. et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J 2006, 151(5): 999-1005.
37. Chenevier-Gobeaux, C., Claessens, Y.E., Voyer, S., Desmoulins, D., Ekindjian, O.G. Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the Emergency Department: comparison with brain natriuretic peptide (BNP). Clin Chim Acta 2005, 361(1-2): 167-75. (Pubitemid 41382620)
38. Thygesen, K., Alpert, J.S., White, H.D. et al. Universal definition of myocardial infarction. Circulation 2007, 116(22): 2634-53. (Pubitemid 350182388)
39. Latini, R., Masson, S., Anand, I.S. et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116(11): 1242-9. (Pubitemid 47517535)
40. Lindahl, B., Toss, H., Siegbahn, A., Venge, P., Wallentin, L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000, 343(16): 1139-47.
41. Heeschen, C., Hamm, C.W., Bruemmer, J., Simoons, M.L. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000, 35(6): 1535-42.
42. Anand, I.S., Latini, R., Florea, V.G. et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005, 112(10): 1428-34. (Pubitemid 41291768)
43. de Boer, R.A., Voors, A.A., Muntendam, P., van Gilst, W.H., van Veldhuisen, D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11(9): 811-7.
44. Frantz, S., Stork, S., Michels, K., Eigenthaler, M., Ertl, G., Bauersachs, J., Angermann, C.E. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 2008, 10(4): 388-95.
45. Cicoira, M., Rossi, A., Bonapace, S. et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004, 10(5): 403-11. (Pubitemid 41080221)
46. Zile, M.R., Desantis, S.M., Baicu, C.F. et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011, 4(3): 246-56.
47. Maisel, A., Xue, Y., Shah, K. et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail 2011, 4(5): 613-20.
48. Tentzeris, I., Jarai, R., Farhan, S. et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail 2011, 13(7): 726-33.
49. Maisel, A., Mueller, C., Nowak, R.M. et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2011, 58(10): 1057-67.
50. Potocki, M., Breidthardt, T., Reichlin, T. et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med 2010, 267(1): 119-29.
51. Maisel, A., Mueller, C., Nowak, R. et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010, 55(19): 2062-76.
52. Kalogeropoulos, A., Georgiopoulou, V., Psaty, B.M. et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 2010, 55(19): 2129-37.
53. Weber, A., Wasiliew, P., Kracht, M. Interleukin-1 (IL-1) pathway. Sci Signal 2010, 3(105): cm1.
54. Dinarello, C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117(14): 3720-32.
55. Ing, D.J., Zang, J., Dzau, V.J., Webster, K.A., Bishopric, N.H. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res 1999, 84(1): 21-33. (Pubitemid 29074877)
56. Suzuki, K., Murtuza, B., Smolenski, R.T., Sammut, I.A., Suzuki, N., Kaneda, Y., Yacoub, M.H. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 2001, 104(12 Suppl. 1): I308-I3.
57. Abbate, A., Salloum, F.N., Vecile, E. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008, 117(20): 2670-83.
58. Siwik, D.A., Chang, D.L., Colucci, W.S. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000, 86(12): 1259-65. (Pubitemid 30436667)
59. Bujak, M., Dobaczewski, M., Chatila, K., Mendoza, L.H., Li, N., Reddy, A., Frangogiannis, N.G. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 2008, 173(1): 57-67. (Pubitemid 351947955)
60. Tominaga, S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989, 258(2): 301-4. (Pubitemid 20001074)
61. Werenskiold, A.K., Hoffmann, S., Klemenz, R. Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol 1989, 9(11): 5207-14. (Pubitemid 19275992)
62. Bergers, G., Reikerstorfer, A., Braselmann, S., Graninger, P., Busslinger, M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994, 13(5): 1176-88. (Pubitemid 24074724)
63. Iwahana, H., Yanagisawa, K., Ito-Kosaka, A. et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999, 264(2): 397-406. (Pubitemid 29424443)
64. Tago, K., Noda, T., Hayakawa, M., Iwahana, H., Yanagisawa, K., Yashiro, T., Tominaga, S. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 2001, 285(5): 1377-83. (Pubitemid 32912936)
65. Tominaga, S., Kuroiwa, K., Tago, K., Iwahana, H., Yanagisawa, K., Komatsu, N. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun 1999, 264(1): 14-8. (Pubitemid 29500455)
66. Yanagisawa, K., Takagi, T., Tsukamoto, T., Tetsuka, T., Tominaga, S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett 1993, 318(1): 83-7. (Pubitemid 23057042)
67. Schmitz, J., Owyang, A., Oldham, E. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23(5): 479-90. (Pubitemid 41587888)
68. Chackerian, A.A., Oldham, E.R., Murphy, E.E., Schmitz, J., Pflanz, S., Kastelein, R.A. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007, 179(4): 2551-5.
69. Palmer, G., Gabay, C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011, 7(6): 321-9.
70. Sanada, S., Hakuno, D., Higgins, L.J., Schreiter, E.R., McKenzie, A.N., Lee, R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117(6): 1538-49. (Pubitemid 46871338)
71. Hayakawa, H., Hayakawa, M., Kume, A., Tominaga, S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007, 282(36): 26369-80. (Pubitemid 47443815)
72. Seki, K., Sanada, S., Kudinova, A.Y., Steinhauser, M.L., Handa, V., Gannon, J., Lee, R.T. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2(6): 684-91.
73. Kumar, S., Tzimas, M.N., Griswold, D.E., Young, P.R. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 1997, 235(3): 474-8. (Pubitemid 27326503)
74. Weinberg, E.O., Shimpo, M., De Keulenaer, G.W. et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 106(23): 2961-6. (Pubitemid 35424749)
75. Miller, A.M., Xu, D., Asquith, D.L. et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205(2): 339-46. (Pubitemid 351281600)
76. Lohning, M., Stroehmann, A., Coyle, A.J. et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998, 95(12): 6930-5. (Pubitemid 28278084)
77. Coyle, A.J., Lloyd, C., Tian, J. et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999, 190(7): 895-902. (Pubitemid 29480818)
78. Townsend, M.J., Fallon, P.G., Matthews, D.J., Jolin, H.E., McKenzie, A.N. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000, 191(6): 1069-76.
79. Oliphant, C.J., Barlow, J.L., McKenzie, A.N. Insights into the initiation of type 2 immune responses. Immunology 2011, 134(4): 378-85.
80. Leung, B.P., Xu, D., Culshaw, S., McInnes, I.B., Liew, F.Y. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004, 173(1): 145-50. (Pubitemid 38797335)
81. Mok, M.Y., Huang, F.P., Ip, W.K. et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010, 49(3): 520-7.
82. Diaz-Jimenez, D., Nunez, L.E., Beltran, C.J. et al. Soluble ST2: a new and promising activity marker in ulcerative colitis. World J Gastroenterol 2011, 17(17): 2181-90.
83. Brunner, M., Krenn, C., Roth, G. et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004, 30(7): 1468-73. (Pubitemid 38951733)
84. Walzl, G., Matthews, S., Kendall, S., Gutierrez-Ramos, J.C., Coyle, A.J., Openshaw, P.J., Hussell, T. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med 2001, 193(7): 785-92. (Pubitemid 32524528)
85. Kearley, J., Buckland, K.F., Mathie, S.A., Lloyd, C.M. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009, 179(9): 772-81.
86. Eggers, K.M., Armstrong, P.W., Califf, R.M., Simoons, M.L., Venge, P., Wallentin, L., James, S.K. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010, 159(5): 788-94.
87. Shimpo, M., Morrow, D.A., Weinberg, E.O., Sabatine, M.S., Murphy, S.A., Antman, E.M., Lee, R.T. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004, 109(18): 2186-90. (Pubitemid 38625395)
88. Bartunek, J., Delrue, L., Van, D.F. et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008, 52(25): 2166-74.
89. Szerafin, T., Brunner, M., Horvath, A. et al. Soluble ST2 protein in cardiac surgery: a possible negative feedback loop to prevent uncontrolled inflammatory reactions. Clin Lab 2005, 51(11-12): 657-63. (Pubitemid 41763084)
90. Pascual-Figal, D.A., Garrido, I.P., Blanco, R. et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann Thorac Surg 2011, 92(6): 2118-24.
91. Ky, B., French, B., McCloskey, K. et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4(2):180-7.
92. Broch, K., Ueland, T., Nymo, S.H. et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail 2012, 14(3): 268-77.
93. Daniels, L.B., Clopton, P., Iqbal, N., Tran, K., Maisel, A.S. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J 2010, 160(4): 721-8.
94. Manzano-Fernandez, S., Mueller, T., Pascual-Figal, D., Truong, Q.A., Januzzi, J.L. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011, 107(2): 259-67.
95. Pascual-Figal, D.A., Manzano-Fernandez, S., Boronat, M. et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011, 13(7): 718-25.
96. Kuroiwa, K., Li, H., Tago, K. et al. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma 2000, 19(2): 151-9. (Pubitemid 30387234)
97. Mueller, T., Dieplinger, B., Gegenhuber, A., Poelz, W., Pacher, R., Haltmayer, M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008, 54(4): 752-6. (Pubitemid 351573718)
98. Dieplinger, B., Januzzi, J.L., Jr., Steinmair, M., Gabriel, C., Poelz, W., Haltmayer, M., Mueller, T. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta 2009, 409(1-2): 33-40.
99. Lu, J., Snider, J.V., Grenache, D.G. Establishment of reference intervals for soluble ST2 from a United States population. Clin Chim Acta 2010, 411(21-22): 1825-6.
100. Potocki, M., Breidthardt, T., Reichlin, T. et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med 2010, 267(1): 119-29.
101. Kelder, J.C., Cowie, M.R., McDonagh, T.A., Hardman, S.M., Grobbee, D.E., Cost, B., Hoes, A.W. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart 2011, 97(12): 959-63.
102. Januzzi, J.L., Jr., Peacock, W.F., Maisel, A.S. et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007, 50(7): 607-13. (Pubitemid 47199007)
103. Dieplinger, B., Gegenhuber, A., Haltmayer, M., Mueller, T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 2009, 95(18): 1508-13.
104. Martinez-Rumayor, A., Camargo, C.A., Green, S.M., Baggish, A.L., O'Donoghue, M., Januzzi, J.L. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol 2008, 130(4): 578-84.
105. Weinberg, E.O., Shimpo, M., Hurwitz, S., Tominaga, S., Rouleau, J.L., Lee, R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107(5): 721-6. (Pubitemid 36222600)
106. Boisot, S., Beede, J., Isakson, S. et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008, 14(9): 732-8.
107. Rehman, S.U., Mueller, T., Januzzi, J.L., Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008, 52(18): 1458-65.
108. Shah, R.V., Chen-Tournoux, A.A., Picard, M.H., van Kimmenade, R.R., Januzzi, J.L. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009, 2(4): 311-9.
109. Pascual-Figal, D.A., Ordonez-Llanos, J., Tornel, P.L. et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009, 54(23): 2174-9.
110. Bayes-Genis, A., de A.M., Galan, A. et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 2012, 14(1): 32-8.
111. Ky, B., French, B., Levy, W.C. et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012, 5(2):183-90.
112. Bayes-Genis, A., Pascual-Figal, D., Januzzi, J.L., Maisel, A., Casas, T., Valdes, C.M., Ordonez-Llanos, J. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol 2010, 63(10): 1171-8.
113. Dieplinger, B., Gegenhuber, A., Kaar, G., Poelz, W., Haltmayer, M., Mueller, T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 2010, 43(9): 714-9.